Search
Talnetant
go.drugbank.com/drugs/DB06429InvestigationalTalnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential
Categories: Heterocyclic Compounds, 2-Ring, Receptors, Neurokinin-3, antagonists & inhibitorsStreptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16711ApprovedInvestigationalIt is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. … Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae
Placental Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15730InvestigationalIt can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. … It was also found that fetal-side pMSCs express different surface markers.
Tangerine peel
go.drugbank.com/drugs/DB14316InvestigationalTangerine peel is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Coconut oil
go.drugbank.com/drugs/DB14322InvestigationalCoconut oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: KATALJİN BUHARLAŞAN MERHEM, 40 G, KATALJİN BUHARLAŞAN MERHEM, 12,5 GSunflower oil
go.drugbank.com/drugs/DB14329InvestigationalSunflower oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Chondrus crispus
go.drugbank.com/drugs/DB14367InvestigationalChondrus crispus is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalAs of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … NasoVAX contains replication-deficient adenovirus vectors in suspension. It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells[L16313].